Telix Pharmaceuticals (TLPPF) Stock Statistics & Valuation Metrics

Telix Pharmaceuticals has a market cap or net worth of $2.56B. The enterprise value is $4.21B.

Telix Pharmaceuticals has 338,831,880 shares outstanding. The number of shares has decreased by -2.65% in one year.

Telix Pharmaceuticals’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is 1.90%.

The current PE Ratio of Telix Pharmaceuticals is ―. Telix Pharmaceuticals’s PEG ratio is 2.81.

In the last 12 months, Telix Pharmaceuticals had revenue of 1.25B and earned -11.05M in profits. Earnings per share was -0.03.

In the last 12 months, operating cash flow was -27.40M and capital expenditures -50.27M, giving a free cash flow of -77.67M billion.

Telix Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Telix Pharmaceuticals upcoming earnings date is Aug 20, 2026, TBA (Confirmed).

Telix Pharmaceuticals as a current ratio of 1.43, with Debt / Equity ratio of 126.06%

In the past 12 months, Telix Pharmaceuticals has paid 2.88M in taxes.

Telix Pharmaceuticals EV to EBITDA ratio is 71.04, with an EV/FCF ratio of -50.88.

Telix Pharmaceuticals has $212.74M in cash and marketable securities with $785.24M in debt, giving a net cash position of -$572.50M billion.

Gross margin is 50.76%, with operating margin of 2.21%, and net profit margin of -0.89%.

The average price target for Telix Pharmaceuticals is $16.68, which is 11.43% higher than the current price. The consensus rating is Strong Buy